Skip to main content

Everolimus-Induced Remission of Classic Kaposi’s Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.

    Article  CAS  Google Scholar 

  2. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.

    Article  CAS  Google Scholar 

  3. Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932–46.

    Article  CAS  Google Scholar 

  4. Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016;128(8):1037–42.

    Article  CAS  Google Scholar 

  5. Serwas NK, Hoeger B, Ardy RC, Stulz SV, Sui Z, Memaran N, et al. Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nat Commun. 2019;10(1):3106.

    Article  Google Scholar 

  6. Egg D, Schwab C, Gabrysch A, Arkwright PD, Cheesman E, Giulino-Roth L, et al. Increased risk for malignancies in 131 affected CTLA4 mutation carriers. Front Immunol. 2018;9:2012.

    Article  Google Scholar 

  7. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nature Reviews Disease Primers. 2019;5(1):9.

    Article  Google Scholar 

  8. Weiss L, Roux A, Garcia S, Demouchy C, Haeffner-Cavaillon N, Kazatchkine MD, et al. Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. J Infect Dis. 1998;178(4):1158–62.

    Article  CAS  Google Scholar 

  9. Colombatti A, Doliana R, Schiappacassi M, Argentini C, Tonutti E, Feruglio C, et al. Age-related persistent clonal expansions of CD28(−) cells: phenotypic and molecular TCR analysis reveals both CD4(+) and CD4(+)CD8(+) cells with identical CDR3 sequences. Clin Immunol Immunopathol. 1998;89(1):61–70.

    Article  CAS  Google Scholar 

  10. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020.

  11. Hou TZ, Verma N, Wanders J, Kennedy A, Soskic B, Janman D, et al. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. Blood. 2017;129(11):1458–68.

    Article  CAS  Google Scholar 

  12. Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat Genet. 2018;50(1):151–8.

    Article  CAS  Google Scholar 

  13. Sterne-Weiler T, Weatheritt RJ, Best AJ, Ha KCH, Blencowe BJ. Efficient and accurate quantitative profiling of alternative splicing patterns of any complexity on a laptop. Mol Cell. 2018;72(1):187–200 e6.

    Article  CAS  Google Scholar 

  14. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med. 1994;180(6):2049–58.

    Article  CAS  Google Scholar 

  15. Leiding JW, Forbes LR. Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. J Allergy Clin Immunol Pract. 2019;7(3):761–73.

    Article  Google Scholar 

  16. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338–47.

    Article  CAS  Google Scholar 

  17. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317–23.

    Article  CAS  Google Scholar 

  18. Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT. Leflunomide with low-dose everolimus for treatment of Kaposi’s sarcoma in a renal allograft recipient. Nephrol Dial Transplant. 2011;26(10):3412–5.

    Article  Google Scholar 

  19. Rukasz D, Krajewska M, Augustyniak-Bartosik H, Letachowicz K, Halon A, Ekiert M, et al. Effective treatment of Kaposi sarcoma with everolimus in a patient with membranous glomerulonephritis. Intern Med J. 2015;45(2):230–1.

    Article  CAS  Google Scholar 

  20. Mourah S, Porcher R, Battistella M, Kerob D, Guillot B, Jouary T, et al. Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma. Br J Dermatol. 2015;173(5):1284–7.

    Article  CAS  Google Scholar 

  21. Garcia-Perez JE, Baxter RM, Kong DS, Tobin R, McCarter M, Routes JM, et al. CTLA4 message reflects pathway disruption in monogenic disorders and under therapeutic blockade. Front Immunol. 2019;10:998.

    Article  CAS  Google Scholar 

  22. Lougaris V, Tabellini G, Baronio M, Patrizi O, Gazzurelli L, Mitsuiki N, et al. CTLA-4 regulates human natural killer cell effector functions. Clin Immunol. 2018;194:43–5.

    Article  CAS  Google Scholar 

Download references


We thank the John Brown Cook Foundation, Jeffrey Modell Foundation, UNSW Triple I SPHERE Clinically Accredited Group, NSW Office of Health and Medical Research, St Vincent’s Clinic Foundation, Allergy and Immunodeficiency Foundation of Australia (AIFA), Garvan-Weizmann Foundation, the David Cooper Memorial Fund, and NHMRC grant ID1155678 for grant support. This work was supported in part with federal funds from the Frederick National Laboratory for Cancer Research, under contract number HHSN261200800001E and NCI contract 75N91019D00024.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tri Giang Phan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yap, J.Y., Gloss, B., Batten, M. et al. Everolimus-Induced Remission of Classic Kaposi’s Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency. J Clin Immunol 40, 774–779 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: